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the models hip fracture was a specific outcome, 94% contained vertebral fractures,
and 77% containedwrist/forearm fractures. Elevenmodels incorporate at least one
extraskeletal effect on cost and survival (including breast cancer, coronary heart
disease, venous thromboembolism, stroke, and colorectal cancer). Thirty-two (32)
of the 48 publications (67%) assume 100% compliance or do not directly mention/
model compliance. The majority of the models take the approach that there was
discontinuation and non-compliance in the clinical trials, and that the treatment
efficacy rates sourced from the clinical trials are underestimated due to the use of
an intention-to-treat paradigm. CONCLUSIONS: The current state of osteoporosis
modeling favors a non-cohort Markov approach, with individualized, i.e., micro-
simulation methodology being increasingly utilized as extraskeletal effects are
incorporated. Treatment compliance and extraskeletal effects are extremely im-
portant in modeling real-world scenarios, yet they are not incorporated into the
majority of the published models. Modeled treatment effectiveness should be
properly imputed to account for the intention-to-treat impact of RCT-reported
values as well as the reduced benefits of treatment noncompliance.
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A COST-EFFECTIVENESS ANALYSIS FROM AN INSTITUTIONAL PERSPECTIVE TO
COMPARE ZOLEDRONIC ACID WITH STANDARD OF CARE IN THE PREVENTION
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OBJECTIVES: Because of its prevalent condition and its association with hip frac-
tures in the elderly population, Osteoporosis has become a major concern for
health authorities in recent years. The objective of this study is to evaluate the
most cost-effective alternative for preventing hip fractures in osteoporosis patients
in Mexico. METHODS: A cost-effectiveness analysis was performed within an insti-
tutional setting (Mexican Institute of Social Security, IMSS). Patients were categorized
into 2 groups by age: group A was comprised with patients ages 60 to 79 years, and
groupBwascomprisedwithpatientsaged80years.Thestandardof carecomparator
usedwasall biphosphonates available in theNational Formulary: risedronate, original
alendronate, generic alendronate, and ibandronate. Resource use data was obtained
frompublished studies; total direct costs of osteoporosis and hip fractures were used.
The source of the unit costs was the institution, current for 2006. All costs are ex-
pressed in local currency (Mexican Pesos, MXP). The time horizon was 10 years; a
discount rate of 3%wasused. Effectiveness datawas obtained frompublished studies;
themeasureusedwaship fractures prevented. Aprobabilistic sensitivity analysiswas
obtained through a Monte Carlo simulation with 100,000 iterations in the weakest
parameters. RESULTS: In both groups, zoledronic acid was the most cost-effective
treatment. In group A, the C/E ratio was $221.43 MXP, as compared with $270.77 for
generic alendronate, $332.50 for ibandronate, $340.24 for risedronate and $353.32
for original ibandronate. Likewise, in group B the C/E ratio for zoledronic acid was
$574.50, as compared to $799.77 for generic alendronate, $941.52 for ibandronate,
$961.38 for risedronate, and $993.89 for original alendronate. The sensitivity anal-
ysis confirmed the robustness of the model. CONCLUSIONS: From an institutional
perspective, zoledronic acid is themost cost-effective alternative for the prevention of
hip fractures in patients with osteoporosis in Mexico.
PMS28
COST-EFFECTIVNESS ANALYSIS OF NSAIDS FOR SYMTOMATIC TREATMENT OF
RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS
Tolubaiev V, Zalis’ka O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
OBJECTIVES: High costs of rheumatoid arthritis (RA) and osteoarthritis (OA) due
not only to high morbidity, disability and mortality levels, but also basis medica-
tions and treatment of adverse events which are very expensive. METHODS: We
analyzed the efficacy and safety data from randomized clinical trials and system-
atic reviews of symptomatic treatment OA and RA patients with meloxicam and
diclofenac. We were searching data on: www.cochrane.org, www.pubmed.gov,
www.clinicaltrials.gov. Amodel “decision tree”was built based on two information
sources: 1) literature review; 2) cost databases. We calculate the average direct
costs of one serious cardiovascular thromboembolic adverse event and one serious
gastrointestinal adverse event in Ukraine. We determined the CER based on costs
from our “decision tree”model and data from the IMPROVE study. RESULTS:Direct
costs of one serious cardiovascular and gastrointestinal adverse event were
USD$590.29 andUSD$613.81 (1 USD$ 7.95UAHon 10.01.2011), respectively. Direct
costs of 60 days symptomatic treatment of 100 RA or OA patients with meloxicam
7.5 mg daily and diclofenac 100 mg daily were USD$2057.99 and USD$4975.22,
respectively. CERmeloxicamwas calculated 30.72 and CER diclofenac - 117.34. The
one-way sensitivity analysis performedwith themost relevant varables confirmed
this tendency. CONCLUSIONS: Results show that Meloxicam 7.5 daily is more eco-
nomical effective versus diclofenac 100 mg daily for symptomatic treatment of RA
and OA patients taking into account probability of serious cardiovascular trombo-
embolic and gastrointestinal adverse events.
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COST-UTILITY ANALYSIS OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,
LIMITED FASCIECTOMY, AND PERCUTANEOUS NEEDLE FASCIOTOMY IN
DUPUYTREN’S CONTRACTURE
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OBJECTIVES: To assess the cost-effectiveness of limited fasciectomy (LF), percuta-
neous needle fasciotomy (PNF), and collagenase clostridiumhistolyticum (CCH) for
the treatment of Dupuytren’s contracture.METHODS: AMarkov model was devel-
oped to simulate Dupuytren’s contracture progression and estimate clinical/eco-
nomic implications of LF, PNF, and CCH treatments from a US healthcare payer
perspective. Transition probabilities were assumed to follow a beta distribution
and were estimated based on results from randomized, clinical trials. Health state
utilities and direct costs of therapies were assumed to follow a gamma distribution
and obtained from published sources. Half-cycle correction was used with a 1-year
cycle length over a 10-year time horizon. One-way sensitivity analyses were per-
formed on relevant variables to test the robustness of the model. Probabilistic
sensitivity analysis was performed using 10,000 trial simulations for all variables
and results were presented as acceptability curves. Themodel used a discount rate
of 3% per annum and reported in 2010 $US dollars. Primary outcomes evaluated
incremental cost-effectiveness ratios. RESULTS: Of the 3 treatment decisions, LF
was the dominant strategy. PNF and CCH were estimated to cost an additional
$247 and $1844 compared to LF, respectively. An expected difference of0.1 and
0.04 quality-adjusted life years (QALYs) were projected for PNF and CCH rela-
tive to LF, respectively. In the one-way sensitivity analysis, the model was sen-
sitive to direct cost of LF with a break-even point of $2000 compared to PNF. The
acceptability curve showed that LF had a higher probability of being cost-effec-
tive compared to other treatment modalities across a WTP threshold of $0 to
$500,000. CONCLUSIONS:Across aWTP threshold between $0 and $500,000, LFwas
themost cost-effective therapy for the treatment of Dupuytren’s contracture com-
pared to PNF and CCH. However, the cost of surgery was sensitive in our model
which may vary from site to site.
PMS30
COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS STANDARD CARE IN THE
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OBJECTIVES: To estimate the cost-effectiveness of denosumab vs. the most com-
monly used therapy (alendronatecolecalciferol) in treatment of post-menopausal
osteoporosis (PMO) in Portugal. METHODS: A Markov cost-utility life-cycle model
with six month cycle length was used. The analysis was undertaken from a Na-
tional Health Service (NHS) perspective. Efficacy data for denosumab was taken
from the FREEDOM randomized double-blind clinical trial and for the comparator
from a meta-analysis conducted by NICE. Epidemiological data were derived from
Portuguese sources and complemented with Swedish data whenever the former
were unavailable. Resource use data were collected through a modified Delphi
panel of Portuguese experts (including rheumatologists, GPs and orthopedic sur-
geons). Resources were valued using various national sources on unit costs. EQ-5D
decrements per fracture were based on the international literature. Expected per-
sistence differences between treatments were also considered. Deterministic sen-
sitivity analysis was conducted on key variables (including costs, utilities, impact
of fractures on mortality, non-inclusion of sub-optimal persistence, comparator’s
price, age and T-score for treatment initiation). Probabilistic sensitivity analysis
was performed on the model’s treatment effects, fracture costs, EQ-5D fracture
decrements and persistence rate differences. RESULTS: Considering an annual
NHS cost of €382.20 for denosumab, the estimated ICER was €14,487 per QALY
gained. The model predicts that, relative to the comparator, denosumab would
prevent 12 hip, 22 vertebral, 2 wrist and 1 other osteoporotic fractures, per 1000
patients, over a 10 year period. Deterministic sensitivity analysis identified the
absence of a persistence effect and the use of generic alendronate price as themost
sensitive parameters (22,906, 20,817 €/QALY, respectively). The probability of cost-
effectiveness ranged between 91% and 64% (willingness to pay set at 50,000 and
20,000 €/QALY, respectively). CONCLUSIONS: Results from the model suggest that,
compared to the most commonly used strategy (alendronatecolecalciferol), de-
nosumab is a cost-effective therapy in the treatment of PMO in Portugal.
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OBJECTIVES: A major challenge facing policy makers is the lack of economic evi-
dence to guide their decisions about allocating health services for neck pain. Our
objective was to evaluate the cost-effectiveness of the most commonly used neck
pain treatments in Canada and the United States. METHODS: We conducted a
cost-utility analysis with a decision-analytic model of 5 treatments for neck pain
(exercise, cyclooxegenase-2 selective inhibitors, manipulation, mobilization, and
nonsteroidal anti-inflammatory drugs [NSAIDs]) using a lifetime time horizon and
adopting a health care system perspective. Model inputs included: estimates of the
course of neck pain; background risk of adverse events in the general population;
treatment effectiveness and risk of cerebrovascular, cardiovascular, and gastroin-
testinal adverse events; quality-of-life weights elicited from neck pain patients
using the standard gamble; and direct and out-of-pocket costs. Costs were ex-
pressed in 2008 Canadian prices. The impact of beneficial and harmful treatment
effects on health were expressed in quality-adjusted life years (QALYs). Cost-effec-
tiveness was estimated with the incremental cost-effectiveness ratio (ICER). The
probability that a given treatment was cost-effective was determined using a will-
ingness-to-pay (WTP) threshold of $50,000 per QALY. RESULTS: Under a conven-
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tional threshold of $50,000 per QALY,manipulationwas cost-effective compared to
NSAIDs (the least costly alternative) (ICER$25,123 per QALY). NSAIDs were most
likely cost-effective at a WTP of $24,000 per QALY whereas manipulation was
most likely cost-effective between $24,000 and $50,000 per QALY. Cyclooxege-
nase-2 selective inhibitors and exercise were subject to simple dominance. The
ICER for mobilization was $381,926 per QALY. Probabilistic sensitivity analyses
suggested a high level of decision uncertainty. CONCLUSIONS: Manipulation is
cost-effective compared to NSAIDs at a conventional threshold of $50,000 per
QALY. Under varying thresholds, NSAIDs are cost effective at $24,000 per QALY.
Wewill identify themain drivers of the uncertainty surrounding the decision about
which treatment to adopt in forthcoming analyses.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic illness that implies high direct
and indirect costs for the health system, particularly when biological therapy is pre-
scribed. The aim of this study was to evaluate the cost-utility of etanercept, adali-
mumab and infliximab for the treatment of rheumatoid arthritis (RA) in Colombian
adult population. METHODS: A cost-utility analysis was performed from a Markov
modelusing3-monthcycles, assumingadult patientswithRA treated for thefirst time
with anti-TNF drugs, in combinationwithmethotrexate (MTX). The time horizonwas
2 years and we used the third party payer perspective. The model was built using
effectiveness, safety and utilitymeasures taken from international registers and clin-
ical trials. Costs were gathered locally and results are expressed in 2010 Colombian
pesos; utility wasmeasured in quality-adjusted life-years (QALY) derived fromACR50
response, compliances rates and adverse events incidence. Drug costs (fixed by regu-
lations fromMinistry of Social Protection) as well as treatment costs of moderate and
serious adverse eventsmainly tuberculosis, pneumonia and cancer included; finally a
univariate sensitivity analysis was carried out. RESULTS: QALY’s gainedwith etaner-
cept, adalimumab and infliximab were 1.4689, 1.4627 and 1.4340, respectively; and
mean estimated costs resulted in US$41, 050, US$43,175 and US$47,190, respectively.
Etanercept was the cost-saving strategy, with a cost-effectiveness ratio of US$27,945/
QALY vs. US$29,520/QALY and US$32,910/QALY in comparison to adalimumab and
infliximab, explained by providing a better safety profile, better adherence to treat-
ment and lower drug costs. The key variables in sensitivity analysis were: drug costs,
frequency of adverse events and compliance rates, and conclusions were unaffected,
even when using extreme values, supporting the robustness of the model.
CONCLUSIONS:TreatmentofRAwithetanerceptMTX is thedominant combination
in Colombia, against adalimumabMTX or infliximabMTX, by providing more
QALYs gained at lower cost.
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OBJECTIVES: To estimate the cost-effectiveness of Abatacept in combination with
Methotrexate (MTX) versus other biologic DMARDs in combination with MTX in
patients with moderate to severe active Rheumatoid Arthritis. METHODS: A se-
quences treatmentmodel was adapted for the representation of disability in terms
of HAQ Index on a 5 year horizon for a cohort of 1000 patients. Abatacept in com-
bination with MTX was compared with etanercept, rituximab, infliximab, adali-
mumab and tocilizumab, all of themassociatedwithMTX. Currency is expressed in
Peruvian soles (S/.) of 2010. RESULTS: The cost of treatment with Abatacept re-
sulted in S/. 169 263 and its effectiveness was found to be 1.96 QALY. Regarding
Etanercept, Adalimumab, Infliximab and Tocilizumab, Abatacept has shown to be
themost effective in terms of QALYs and the least expensive. Regarding Rituximab,
Abatacept has an incremental cost effectiveness ratio of S/. 75 493 perQALY gained.
CONCLUSIONS:According to thismodel and inputs, Abataceptwas found to be dom-
inant against Etanercept, Adalimumab, Infliximab y Tocilizumab, from the Health
Social Security (EsSalud) perspective for the treatment of moderate to severe active
Rheumatoid Arthritis in patients who have failed to MTX based treatment.
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OBJECTIVES: Denosumab has recently been approved in the United States for the
treatment of postmenopausal women with ostepoporosis. Denosumab, a twice
yearly 60mg injection, provides an opportunity to model the effect of improved
treatment persistence on outcomeswhen compared to the daily dosing required of
patients on 60mg raloxifene, also a second line osteoporotic therapy.METHODS: A
previously developed Markov model was used to simulate outcomes for post-
menopausal women aged 65 with a bone mineral density (BMD) of less than 2.5.
We assumed a 20-year time horizon and a managed care perspective. Modeled
health states included vertebral, hip, and wrist fractures. Disease progression pa-
rameterswere derived fromphase III clinical trials. Costswere obtained using large
epidemiologic studies. Quality-adjusted life-years (QALYS) were used to assess
outcomes, and utility weights were derived from recent systematic reviews detail-
ing utility values associated with various osteoporotic fracture states. RESULTS:
Denosumab is dominated by raloxifene, as indicated by higher costs and poorer
outcomes. Persistence rates associated with both treatments had the greatest im-
pact on resulting incremental cost-effectiveness ratios. Estimated 20-year aggre-
gated costs and QALYs per person using denosumab are $26,123 and 12.63, respec-
tively compared to $23,670 per person and 13.05 per person for raloxifene. The ICER
was most sensitive to changes in persistence rates. Raloxifene was universally
dominant under all one-way sensitivity analysis scenarios. CONCLUSIONS: Deno-
sumab is not cost-effective compared to raloxifene. Further research should assess
whether the costs associated with improved denosumab persistence are offset by
reduced fracture rates and costs of fracture treatment.
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OBJECTIVES: The objective of this research was to assess the cost-effectiveness of
Chondroitin Sulphate (CS) used as treatment of Osteoarthritis (OA) of the knee in
mexican patients from the Mexican Public Health Institution perspective.
METHODS:We developed a Markov analytical model for a cohort with 10 years to
assess costs and benefits associated with the use of CS in the treatment of OA in
Mexicans patients. Comparator for CS was normal care (gold standard treatment).
Effectiveness measure was QALYs. These values were estimated by literature re-
view validated by expert panel consensus. The direct costs, treatment of adverse
events and knee surgery in the treatment of OA were estimated. The unitary costs
were obtained from the Mexican public health institutions. All costs were calcu-
lated in 2010 Mexican Pesos (MXP). Incremental-cost-effectiveness-ratios were ex-
pressed as cost per quality-adjusted-life-year (QALY). Costs and QALYs were dis-
counted at 5%. Probabilistic sensitivity analyses via Monte Carlo simulations were
undertaken to incorporate likely distributional properties of key model
parameters. RESULTS: The QALYS increased with CS on 4.89 and with standard
treatment on 4.73. Total treatment to include CS costs increased $25,470.13 MXP,
resulting in an incremental cost per QALY in $158,587.77 MXP. This incremental
cost utility is less than 1 Mexican PIB per capita. Deterministic and probabilistic
sensitivity analyses showed the robustness of the results. CONCLUSIONS: CS is a
cost efficient and useful for the treatment of OA in public health systems
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EXAMINING THE RELATIONSHIP BETWEEN MONTHLY OUT-OF-POCKET
HEALTHCARE COSTS AND WORK PRODUCTIVITY AMONG INDIVIDUALS WITH
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OBJECTIVES: The relationship between out-of-pocket (OOP) healthcare costs with
productivity is not well known. This study explores the relationship of OOP health-
care costs on productivity.METHODS: Participants self-identifiedwith RA and aged
18 completed an internet-based cross-sectional survey in 1Q2009. Self-reported
productivity loss including absenteeism, presenteeism, overall work impairment
and activity impairment expressed as impairment percentages, weremeasured by
the Work Productivity and Activity Impairment questionnaire. Participants were
asked about RA-related and overall monthly OOP healthcare costs. Negative bino-
mial regressionmodelswere developed to adjust for age, gender, ethnicity, income,
education, andmarital status.RESULTS: 455 RApatients participated in the survey.
Average age was 52 years, 67% were female, 36% were employed, and 23% were on
short- or long-term disability. More than half (53%) reported annual household
incomes between $50-100K, and 30% were college educated. Overall monthly OOP
costs were: $0-$50 for 54.1%, $51-$100 for 19.3%, $101-$200 for 15.8%, and$200 for
10.8%. Among employed patients, the rates of absenteeism, presenteeism, and
overall work impairment were 13.7%, 23.7% and 28.9%, respectively. Both em-
ployed and unemployed patients reported 58.4% impairment in daily activities.
Significantly greater productivity loss (presenteeism, b  1.01, p  0.038) and ac-
tivity impairment (b  0.21, p  0.006) were observed among patients with overall
OOP costs $200, and significantly greater activity impairment was observed
among theOOP costs category of $101-200 (b 0.15, p 0.026) as compared to those
with OOP costs between $0-50 after adjusting for patient demographics.
CONCLUSIONS: Higher monthly OOP costs were associated with higher activity
impairment and lower productivity; however, due to cross-sectional study design,
direction of associations cannot be determined. Shifting healthcare costs to em-
ployees may be associated with productivity loss. Further research is needed to
determine long-term impact of OOP healthcare costs on work productivity.
Muscular-Skeletal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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TREATMENT OF PSORIATIC ARTHRITIS
Kirson N1, Rao S2, Birnbaum HG1, Kantor E1, Wei R1, Cifaldi M2
1Analysis Group, Inc., Boston, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA
A129V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
